Timothy M. Pawlik
Deputy Editor at JAMA Surgery
Chair @OhioStateSurg, surgeon-in-chief @OSUWexMed and professor @OhioStateMed. Sharing news from DoS. Boston sports fan. Tweets are my own. #OhioStateSurg
Articles
-
1 month ago |
jamanetwork.com | Diamantis I. Tsilimigras |Timothy M. Pawlik
Molecular Testing and Targeted Therapies in Hepatobiliary Cancers: A Review Podcast (12:47) 0:00 / 0:00 Abstract Importance Hepatobiliary cancers are heterogeneous and molecularly complex.
-
1 month ago |
jamanetwork.com | Diamantis I. Tsilimigras |Timothy M. Pawlik
Importance Hepatobiliary cancers are heterogeneous and molecularly complex. Recent advances in next-generation sequencing (NGS) have enhanced the understanding of their molecular landscape and enabled deployment of biomarker-based gene- and immune-targeted therapies. This review examines the role of molecular testing and targeted therapies in these malignant neoplasms. Observations Patients with hepatobiliary cancers have poor outcomes.
-
1 month ago |
jamanetwork.com | Rachel A. Greenup |Danny Chu |Timothy M. Pawlik
In the US, individuals with commercial insurance or Medicare-based plans make up approximately 55% and 20% of the population, respectively.1 As a result, administrative and billing data sources are collected by health care organizations, institutions, or government agencies to manage the administrative and financial aspects of health care services. These datasets robustly characterize billable services for individuals receiving inpatient and outpatient medical care and rely on billable codes.
-
2 months ago |
ejso.com | Timothy M. Pawlik
Keywords Colorectal cancer Gene signature Overall survival Therapeutic target Machine learning INTRODUCTION Despite advancements in the diagnosis and treatment of patients with colorectal cancer (CRC), mortality remains relatively high.1 In fact, up to 50% of patients develop metastatic CRC (mCRC) at some point in the course of their disease with a subsequent 5-year survival of only 15-40%.2,3 Traditionally, clinicopathological predictors, such as tumor size as well as Tumor/Node/Metastasis...
-
2 months ago |
ejso.com | Timothy M. Pawlik
Key wordsHepatocellular Carcinoma (HCC)HepatectomyTumor sizeImagingPathologyCancer-specific survival (CSS)Get full text accessLog in, subscribe or purchase for full access. References1. Galle, P.R. ... EASL clinical practice guidelines: management of hepatocellular carcinomaJournal of hepatology. 2018; 69:182-2362. Reig, M. ... BCLC strategy for prognosis prediction and treatment recommendation: The 2022 updateJournal of hepatology. 2022; 76:681-6933. Maki, H. ∙ Hasegawa, K.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 7K
- Tweets
- 2K
- DMs Open
- No
Big #Congratulations to @OhioStateSurg @OhioStatePIIO faculty member Dr. Glen Barber. Today we had a chance to celebrate and recognize him for his recent receipt of #Germany 🇩🇪 most prestigious research Ehrlich-Darmstaedter award 🏆for the discovery of STING pathway. 🎉 https://t.co/xuIj1ilE4w
Excited that @DrMemeh will be joining #THE @OhioStateSurg as an assistant professor of #Surgery in the Division of Surgical Oncology. Having completed an endocrine fellowship @uchicagosurgery he will join our #endocrine 🦏 TEAM! Welcome to #BuckeyeNation! ⭕️🙌 https://t.co/b1L9ZNoFz8
Enjoyed being back in my “home” #BeanTown #Boston as combined @MGHSurgery @MGHCancerCenter Visiting Professor. ❤️seeing old friends & mentors, as well as spending time with next generation of #surgical #leaders. Big 🙏 to Dr. Lillemoe for being as kind & gracious as always. 🎁 https://t.co/BBKMwLYpmJ
